logo
Beat the heat with these cooling gadgets and wearables

Beat the heat with these cooling gadgets and wearables

CTV News12-07-2025
This image released by Warmies shows plush animal toys that can be popped in the freezer to provide cooling comfort. (Warmies via AP)
You can only sit in front of the fridge with the door open for so long.
As heat waves blast the world like a blow dryer on high, folks are reaching for anything that promises a little personal chill: portable mini fans, cooling neck wraps, high-tech vests and all kinds of heat-beating headwear.
Of course, cooling gear helps most when paired with basic and safe strategies against the heat: most importantly hydration, shade and rest. Stay out of extreme heat when possible, and know the signs of heat exhaustion or heat stroke.
Yet these wearable wonders and breezy gadgets can offer some relief. They might look quirky, but when the AC struggles and the sidewalk feels like a stovetop, they can start to seem like must-haves.
When you're at home
Indoors, stay comfy with cool-feel sheets (like those with a silky finish or lightweight fibers), bed fans (where a nozzle inserted into the bed linens pumps a flow of air around you), or a cooling pillow or chill pad, which are filled with a gel that can stay cool for hours. Sleep-product brands include Serta, Sealy, Casper, Pluto and Threshold.
The chill pads can work for your own bed and the pets' bed too. There are chillable full-size mattresses (Chilipad, 8Sleep and BedJet get good reviews from The Spruce) and smaller, simple pads (CoolCare and Sharper Image, among others).
Outdoor wearables
Clare Epstein, an employee safety expert with Vector Solutions in Tampa, Florida, works to reduce heat stress for at-risk employees in industries like construction, aviation and agriculture. She recommends wearables like cooling scarves and evaporative cooling vests.
'By soaking the fabric in cold water at the beginning of the day, the vest slowly cools, and keeps the wearer cool,' she says.
Clothes made of 'phase change materials,' or PCMs, contain gel capsules or pads that can help moderate body temperatures. Uline.com advertises a vest that stays under 60 degrees for a few hours, and AlphaCool offers a neck tube that performs similarly. Another feature of the tube, which is made of a polymer material, is that it doesn't get overly chilled, so it's safe for kids to use.
Also for kids, there's a line of plush toys from Warmies that includes little critters of the farmyard, ocean, forest and safari that can be popped in the freezer before a trip to the park or playground.
Wearable items that incorporate small fans or thermoelectric coolers are also good, Epstein says. And there are vests with tubed reservoirs you can fill with water or electrolytes so you can sip as you go.
'These encourage people to take more water breaks, and stay hydrated,' says Epstein.
The wearables range is extensive. Along with cooling buffs, headbands, wristbands, socks and scarves, there are cooling brimmed hats and ball caps. Brands include Mission, Ergodyne, and Sunday Afternoon.
If you'd prefer a refreshing breeze, USB-chargeable handheld or wearable fans might do the job.
The Campbell family of Calgary
This undated photo shows the Campbell family, wearing sun protection shirts and hats, posing for a photo during a hike in the Rocky Mountains near their Calgary, Alberta home, (Lynn Campbell via AP)
(Photo: AP/Campbell family)
Chill advice
Lynn Campbell, co-founder of 10Adventures travel company in Calgary, Alberta, takes a lot of strenuous hiking and cycling trips with her husband, Richard. They've developed some easy hacks for hot days.
'We'll wake up early, so we're done by 10 or 11 a.m., or if we're out on the trails, split the day in two, so we rest by water or in the shade over the hottest part' of the day, she says.
Wear light colors and thin, breathable fabrics.
And bring an umbrella. 'This is a game-changer,' Campbell says. 'Now we always pack ultralight, compact ones; they're incredible.'
Also, pour cool water on your head and back. 'We freeze a few bottles of water so we can pour ice water on us to cool down,' Campbell says. 'Putting the bottles under the armpits, in the groin, or on the back of the neck can effectively cool a person down.'
And Annita Katee, a contributing writer for Apartment Therapy, has another way to prep your bed on hot nights:
'Pop your sheets into the freezer at least two hours before bedtime, then pull them out right before you hit the sack,' she wrote in a recent post. She folds hers into a zipped plastic bag, flattens it, then sets it on a freezer shelf between ice packs.
'The result? A delightfully cool bed that feels like a refreshing oasis against the heat.'
___
New York-based writer Kim Cook covers design and decor topics regularly for The AP. Follow her on Instagram at @kimcookhome.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Cutaneous T-Cell Lymphoma Pipeline Outlook Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape
Cutaneous T-Cell Lymphoma Pipeline Outlook Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape

Globe and Mail

time14 hours ago

  • Globe and Mail

Cutaneous T-Cell Lymphoma Pipeline Outlook Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight's ' Cutaneous T-cell lymphoma Pipeline Insight 2025 ' report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in the Cutaneous T-cell lymphoma pipeline landscape. It covers the Cutaneous T-Cell Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Cutaneous T-Cell Lymphoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Cutaneous T-Cell Lymphoma Treatment Landscape. Click here to read more @ Cutaneous T-Cell Lymphoma Pipeline Outlook Key Takeaways from the Cutaneous T-Cell Lymphoma Pipeline Report In July 2025, Prescient Therapeutics Ltd. announced a phase 2 study to evaluate the efficacy, safety, pharmacokinetics (PK) and pharmadynamics (PD), of PTX-100 monotherapy at 500 or 1000 mg/m2 in patients with relapsed/refractory Cutaneous T-Cell Lymphoma (CTCL). In July 2025, Dren Bio conducted a Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of DR-01 in adult patients with large granular lymphocytic leukemia or cytotoxic lymphomas. In July 2025, Soligenix announced a Phase 3 study is to evaluate the ability of an 18-week course of HyBryte and visible light to induce a Treatment Response in patients with patch/plaque phase CTCL compared to patients receiving placebo and visible study will evaluate the efficacy and safety of HyBryte (0.25% hypericin) gel or placebo gel applied twice weekly for 18 weeks. Treated lesions will be covered with opaque material (such as opaque clothing), followed 21 (±3) hours later by the administration of visible light. DelveInsight's Cutaneous T-Cell Lymphoma pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Cutaneous T-Cell Lymphoma treatment. The leading Cutaneous T-Cell Lymphoma Companies such as HyBryte, Resminostat, Mundipharma International, Shanghai Pharmaceuticals Holding, Moleculin Biotech, Inc., BeiGene, Mundipharma Research Limited, Jiangsu Simcere Biologics Co., Ltd, Teva Pharmaceuticals USA, Pfizer, Galderma R&D, Merck Sharp & Dohme LLC, Bio-Path Holdings, Inc., Kymera Therapeutics, Inc., Karyopharm Therapeutics Inc ​ and others. Promising Cutaneous T-Cell Lymphoma Pipeline Therapies such as E7777, CD11301 0.03%, Panobinostat, ONTAK (denileukin difitox, DAB389IL-2), Quisinostat, 12 mg, APO866, Enzastaurin, SGX301 (synthetic hypericin), Mogamulizumab, Romidepsin (depsipeptide, FK228), and others. Stay informed about the cutting-edge advancements in Cutaneous T-Cell Lymphoma Treatments. Download for updates and be a part of the revolution in oncology care @ Cutaneous T-Cell Lymphoma Clinical Trials Assessment Cutaneous T-cell lymphoma Emerging Drugs HyBryte™ (synthetic hypericin or SGX301) is a novel, first-in-class, photodynamic therapy utilizing safe, visible light for activation. The active ingredient in HyBryte™ is synthetic hypericin, a potent photosensitizer that is topically applied to skin lesions that is taken up by the malignant T-cells, and then activated by visible light approximately 24 hours later. The use of visible light in the red-yellow spectrum has the advantage of penetrating more deeply into the skin (much more so than ultraviolet light) and therefore potentially treating deeper skin disease and thicker plaques and lesions. Synthetic hypericin sodium, the active ingredient in HyBryte™, has Orphan Drug designation in the United States for the treatment of T-cell lymphoma and CTCL and in Europe for CTCL. HyBryte™ has received Fast Track designation for the treatment of cutaneous t-cell lymphoma in the United States. AFM13: Affimed GmbH AFM-13 is under development for the treatment of refractory and relapsed Hodgkin lymphoma, CD30+ lymphoma such as transformed mycosis fungoides, peripheral and cutaneous T-cell lymphoma, large B-cell lymphoma, B-cell non-Hodgkin lymphoma, Hodgkin lymphoma combination with check point inhibitors and Hodgkin lymphoma combination with lenalidomide. The drug candidate is administered intravenously. AFM-13 is a bi-specific, tetravalent human antibody, it acts by targeting CD30/CD16A. The drug is currently in Phase II stage of its development for the treatment of Cutaneous T Cell Lymphoma. ASTX660: Otsuka Pharmaceutical Co., Ltd ASTX660 (Tolinapant) is a novel, orally administered, non-peptidomimetic antagonist of the cellular and X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP). Inhibitors of apoptosis proteins (IAPs) are frequently overexpressed in tumor cells and contribute to tumor cell survival and chemo-resistance. By inhibiting IAPs, tolinapant promotes cell death. Tolinapant also acts via a newly described immunomodulatory mechanism, which works to enhance an anti-tumor immune response in T-cell lymphomas. The drug is in Phase I/II for the treatment of CTCL. WUCART007: Wugen WU-CART-007 is an allogeneic, off-the-shelf, fratricide-resistant CD7-targeted CAR-T cell therapy engineered to overcome the technological challenges of harnessing CAR-T cells to treat CD7+ hematological malignancies. Wugen is deploying CRISPR/Cas9 gene editing technology to delete CD7 and the T-cell receptor alpha constant (TRAC), preventing CAR-T cell fratricide and mitigating the risk of graft-versus-host-disease (GvHD). WU-CART-007 is manufactured using healthy donor-derived T-cells to eliminate the risk of malignant cell contamination historically observed in the autologous CAR-T setting. Currently, the drug is in Phase I stage of its clinical trial for the treatment of CTCL. The Cutaneous T-Cell Lymphoma pipeline report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Cutaneous T-Cell Lymphoma with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cutaneous T-Cell Lymphoma Treatment. Cutaneous T-Cell Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Cutaneous T-Cell Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cutaneous T-Cell Lymphoma market. Get a detailed analysis of the latest innovations in the Cutaneous T-Cell Lymphoma pipeline. Explore DelveInsight's expert-driven report today! @ Cutaneous T-Cell Lymphoma Unmet Needs Cutaneous T-Cell Lymphoma Companies HyBryte, Resminostat, Mundipharma International, Shanghai Pharmaceuticals Holding, Moleculin Biotech, Inc., BeiGene, Mundipharma Research Limited, Jiangsu Simcere Biologics Co., Ltd, Teva Pharmaceuticals USA, Pfizer, Galderma R&D, Merck Sharp & Dohme LLC, Bio-Path Holdings, Inc., Kymera Therapeutics, Inc., Karyopharm Therapeutics Inc ​ and others. Cutaneous T-cell lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Oral Intravenous Subcutaneous Parenteral Topical Cutaneous T-Cell Lymphoma Products have been categorized under various Molecule types such as Recombinant fusion proteins Small molecule Monoclonal antibody Peptide Polymer Gene therapy Discover the latest advancements in Cutaneous T-Cell Lymphoma Treatment by visiting our website. Stay informed about how we're transforming the future of oncology @ Cutaneous T-Cell Lymphoma Market Drivers and Barriers, and Future Perspectives Scope of the Cutaneous T-Cell Lymphoma Pipeline Report Coverage- Global Cutaneous T-Cell Lymphoma Companies- HyBryte, Resminostat, Mundipharma International, Shanghai Pharmaceuticals Holding, Moleculin Biotech, Inc., BeiGene, Mundipharma Research Limited, Jiangsu Simcere Biologics Co., Ltd, Teva Pharmaceuticals USA, Pfizer, Galderma R&D, Merck Sharp & Dohme LLC, Bio-Path Holdings, Inc., Kymera Therapeutics, Inc., Karyopharm Therapeutics Inc and others. Cutaneous T-Cell Lymphoma Pipeline Therapies- E7777, CD11301 0.03%, Panobinostat, ONTAK (denileukin difitox, DAB389IL-2), Quisinostat, 12 mg, APO866, Enzastaurin, SGX301 (synthetic hypericin), Mogamulizumab, Romidepsin (depsipeptide, FK228), and others. Cutaneous T-Cell Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Cutaneous T-Cell Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of Cutaneous T-Cell Lymphoma Pipeline on our website @ Cutaneous T-Cell Lymphoma Emerging Drugs and Companies Table of Content Introduction Executive Summary Cutaneous T-cell lymphoma: Overview Pipeline Therapeutics Therapeutic Assessment Cutaneous T-cell lymphoma– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Drug Name: Company Name Mid Stage Products (Phase II) AFM13: Affimed GmbH Early Stage Products (Phase I) WUCART007: Wugen Preclinical Stage Products Drug Name: Company Name Inactive Products Cutaneous T-cell lymphoma Key Companies Cutaneous T-cell lymphoma Key Products Cutaneous T-cell lymphoma- Unmet Needs Cutaneous T-cell lymphoma- Market Drivers and Barriers Cutaneous T-cell lymphoma- Future Perspectives and Conclusion Cutaneous T-cell lymphoma Analyst Views Cutaneous T-cell lymphoma Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:

Londoners urged to check on vulnerable as temperatures soar under the sizzling sun
Londoners urged to check on vulnerable as temperatures soar under the sizzling sun

CTV News

time16 hours ago

  • CTV News

Londoners urged to check on vulnerable as temperatures soar under the sizzling sun

Local Ark Aid Mission sets up system to help provide critical relief from the heat. CTV London's Reta Ismail has the story. With a heat warning in effect and temperatures soaring, local health officials and outreach organizations are urging Londoners to take precautions and help protect the most vulnerable members of the community. Environment Canada issued a heat warning for the region, forecasting daytime highs between 30 and 33 degrees with humidex values reaching as high as 42. Overnight lows are expected to stay above 19, offering little relief. The heat wave is expected to persist through Tuesday night. In downtown London, the Ark Aid Mission has added a shaded patio and makeshift misting station to help people experiencing homelessness cool off. Steven, who is currently unhoused, says it makes a big difference. 'It keeps you cool, and they give shade,' he said. 'There's no other shade in the city except for trees. And, without it, I don't think a lot of people would survive, to tell you the truth.' Sarah Campbell, executive director of Ark Aid Mission says they are doing what they can to help during the heat warning. She added that the Ark Aid is funded for just four hours of daily service but is operating 8 hours Monday through Friday, and 12 hours on Saturday and Sunday. 'Much like our winter planning, we look to find ways to get people indoors, give them an opportunity to rest, make sure that they have proper nourishment,' she said. 'We are working with our partners to make sure there's an everyday location for lunch and dinner and breakfast. We really try to just take those basic needs one by one, having a shower, access to running water, a bathroom.' The Middlesex-London Health Unit is reminding residents that extreme heat can be dangerous and even deadly especially for the elderly, infants and people without adequate housing. 'It can start with symptoms such as sweating, just some general fatigue and cramps and stuff like that,' said Dave Pavletic, manager of environmental health at the health unit. 'And then it could lead to some more significant symptoms, which can be heatstroke which is a medical emergency.' Pavletic encourages residents to take it easy, avoid strenuous outdoor activity and check in on others who may be at risk. 'You want to make sure that you check on family and friends, particularly folks that are elderly and may not have air conditioning, because the indoor heat can be a significant concern too,' he said. Environment Canada says relief is on the way, with slightly lower temperatures expected by Wednesday.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store